Clinical Trial Detail

NCT ID NCT04107103
Title Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma (NivoPlus)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AHS Cancer Control Alberta
Indications

head and neck squamous cell carcinoma

Therapies

Nivolumab + Pemetrexed Disodium

Age Groups: senior adult

No variant requirements are available.